Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

Insulet Corporation (PODD) is primed for growth in the coming quarters as its revolutionary Omnipod 5 offering continues to successfully drive market growth. The company is making remarkable progress in terms of its key strategic imperatives to help patients in their diabetes management. Sound financial stability further instills optimism. The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $13.46 billion. Insulet projects a long-term estimated earnings gro ...